OTC dextromethorphan abuse potential
Executive Summary
Will be addressed by the Drug Abuse Advisory Committee at its July 14 meeting. An August 1990 review of the antitussive ingredient dextromethorphan (A. H. Robins' Robitussin) prompted a request by the committee for more epidemiologic data on its abuse. The morning of July 15, the committee "will discuss procedures and policies for, and approaches to, the study of hallucinogenic drugs." The afternoon session is closed to the public.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth